Generation Bio Co reports results for the quarter ended June 30 - Earnings Summary

• Generation Bio Co GBIO.OQ reported a quarterly adjusted loss of $3.12​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-3.10. The mean expectation of six analysts for the quarter was for a loss of $2.85 per share. Wall Street expected results to range from $-3.30 to $-2.20 per share.

• Revenue fell 81.3% to $765.00 thousand from a year ago; analysts expected $3.10 million.

• Generation Bio Co's reported EPS for the quarter was a loss of $3.12​.

• The company reported a quarterly loss of $20.92 million.

• Generation Bio Co shares had risen by 26.2% this quarter and lost 61.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Generation Bio Co is $75.00, about 94.6% above its last closing price of $4.04

This summary was machine generated from LSEG data August 12 at 08:48 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)